News

Video

Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LA

Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.

Related Videos
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
4 KOLs are featured in this series
4 KOLs are featured in this series
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
utinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis